Skip to content

Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia

Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02396979
Acronym
Harapan
Enrollment
300
Registered
2015-03-24
Start date
2010-01-31
Completion date
2014-12-31
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immunodeficiency Syndrome, Drug Dependence, Human Immunodeficiency Virus, Opiate Addiction

Brief summary

The purpose of this study is to evaluate the relative impact a medical drug (methadone) or behavioral counseling program (Holistic Health Recovery Program) or both (methadone and Holistic Health Recovery Program) has on reducing HIV-related risk behaviors and illicit drug use among opioid-dependent, HIV-infected individuals in prison when given 90 to 180 days prior to leaving prison.

Interventions

DRUGMethadone
BEHAVIORALHolistic Health Recovery Program

Sponsors

University of Malaya
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV-infected * Clinical Diagnosis of Opioid Dependence * Fluent in Bahasa Malaysia or English * Within 90 to 180 days of release from prison * Planning to live in Klang Valley region after release from prison * Able to provide informed consent

Exclusion criteria

* Pregnancy or planning to become pregnant (female only)

Design outcomes

Primary

MeasureTime frameDescription
HIV Risk EventsChange from Baseline in HIV Risk Events at Months 3, 6, 9 and 12The primary outcome is the number of HIV high risk events. This outcome will be constructed from a composite measure counting the number of unprotected vaginal and anal insertive events and needle-or-syringe-sharing events with an HIV- or HIV-status-unknown partner that might result in HIV transmission to an uninfected partner. As such, the primary outcome will be the number of high-risk events during the period of observation in the intervention. All data will be self-reported by the participant.

Secondary

MeasureTime frameDescription
HIV Quality of LifeChange from Baseline in HIV Quality of Life at Months 3, 6, 9 and 12This outcome will be measured by a series of questions that will be used to produce a composite score that will indicate the participant's overall quality of life as it relates to their HIV status. These questions will ask about your general health and your ability to perform daily activities in your life. All data will be self-reported by the participant.
Relapse to Drug UseChange from Baseline in Relapse to Drug Use at Months 3, 6, 9 and 12This outcome will be measured as any opioid drug use after release from prison. This outcome will be measured in two ways. First, participants will provide a monthly urine sample that will be tested for the presence of opioids. Second, participants will answer questions about their drug use since the time of their last interview.
Addiction SeverityChange from Baseline in Addiction Severity at Months 3, 6, 9 and 12This outcome will be measured by a series of questions about the participant's drug use. These questions will be used to produce a composite score which indicates the severity of the participant's addiction.
ReincarcerationAny reincarceration to prison during the 12 month post-release follow-up periodThis outcome will be measured by both self-report and objective data from the Malaysian Ministry of Prisons. Self-report questions will be used to ask participants if they have been arrested by police (placed in jail) or incarcerated in prison during the time since the last interview. Objective data will also be obtained from the Ministry of Prisons which will indicate if the participant has been reincarcerated in one of Malaysia's prison during the 12 months since they were initially released from prison.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026